The synthesis of five 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives was accomplished by refluxing 2-amino-3-bromo-1,4-naphthoquinone with appropriate benzoyl chloride analogs at elevated temperatures. In vitro anticancer evaluation of these compounds was performed on androgen-dependent, LNCaP, and androgen-independent, PC3, human prostate cancer cell lines. In general, these compounds displayed slightly stronger cytotoxicity on the androgen-dependent LNCaP than on the androgenindependent PC3 prostate cancer cell lines. The metasubstituted 2-(3-Chloro-phenyl)-naphtho [2,3-d]oxazole-4,9-dione (10) appear to display the best cytotoxicity on both cell lines with an IC 50 of 0.03 μM on LNCaP and 0.08 μM on PC3 after 5 days of exposure.
Introduction
The quinone moiety is an important part of many biologically active natural products and their synthetic analogs. Both natural and synthetic quinones have been shown to exhibit a variety of biological activities, including anticancer activities. For example, anti-cancer drugs containing the quinone moiety such as mitomycin C (1) daunorubicin (2), doxorubicin (3) and mitoxantrone (4) have been used in the treatment of various types of cancers, including solid tumors, for many years [1, 2] . Quinonoid compounds are ideal for cancer chemotherapies as selective toxicity is obtained through a variety of pathways including DNA intercalation, alkylation of bio-nucleophiles, apoptosis induction, enzymatic inhibition (especially Topoisomerase II inhibition), and generation of reactive oxygen species through redox cycling [1, 2] . More recently, several quinone-containing compounds have been developed as inhibitors of enzymes and/or pathways implicated in cancer development and survival. These include inhibitors of heat shock proteins (Hsp90) [3] , protein phosphatases (CDC25A, CDC25B, CDC25C) [4] [5] [6] , and indoleamine-2,3-dioxygenase (IDO, an immunosuppression enzyme implicated in immune escape strategy of many tumors) [7] . In addition, some quinonoids have been reported to target the human telomerase [8, 9] , microtubule polymerization [10, 11] , and the two-electron reductase NQO1 (DTdiaphorase) [12, 13] . We have previously developed 2-chloro-3-(N-succinimidyl)-1,4-naphthoquinone (5) and some of its analogs as MEK1 specific inhibitors of the Ras-MAPK pathway [14] . We subsequently reported the anti-carcinogenic activities of some of these imidosubstituted 2-chloro-1,4-naphthoquinone derivatives on androgen-dependent, LNCaP, and androgen-independent, PC3 and DU145, human prostate cancer cell lines [15] . Similarly, we have studied the anticancer activity of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone on some breast and prostate cancer cell lines [16, 17] . In continuation of our work on developing novel quinones for study in our prostate and breast cancer drug development program, we here report the synthesis of some novel aryl-substituted oxazolo-1,4-naphthoquinone (2-arylnaphtho [2,3-d] oxazole-4,9-dione) derivatives and their anticancer effects on LNCaP (androgen dependant) and PC3 (androgen-independent) human prostate cancer cell lines.
Experimental procedure

Materials
All reactions were carried out using laboratory grade materials and solvents. Purification was done by trituration in 100% diethyl ether or a mixture of diethyl ether/hexane followed by column chromatography on silica gel. Melting points were determined in open capillary tubes on a Mel-Temp melting point apparatus and are uncorrected. The IR spectra were recorded on a Perkin Elmer PE 100 spectrometer with an Atenuated Total Reflectance (ATR) window. The 1 H-and 13 C-NMR spectra were obtained on a Bruker Avance 400 MHz spectrometer in deuterated chloroform (CDCl 3 ) or deuterated dimethyl sulfoxide (DMSO-d 6 C-NMR. High resolution electrospray ionization mass spectrometry was recorded on a Jeol AccuTOF-CS ESI-TOF. Dichloromethane was used as the solvent, and all the mass spectra showed signals corresponding to the molecular ion plus proton (H + ). The known intermediates were prepared according to procedures that are reported in the literature. 2-Amino-3-bromo-1,4-naphthoquinone was prepared by refluxing commercially available 2,3-dibromo-1,4-naphthoquinone with ammonia/ammonium hydroxide mixture in ethanol.
In vitro cytotoxicity assay Assessment of cytotoxicity The MTT cell proliferation assay was employed in assessing the cytotoxicity profiles of the analogs. All the cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, penicillin-streptomycin, gentamycin, sodium pyruvate, glutamine and non essential amino acids and grown at 37°C in 5% CO 2 humidified environment. PC-3 cells were seeded into 96-well plates (except for wells that served as blank control) at a density of 1.5×10 4 cells per well. On the other hand, the slow-growing LNCaP cells were seeded at a density of 2. Chemical synthesis 2-phenyl-naphtho [2,3-d] oxazole-4,9-dione (8) A mixture of 2-amino-3-bromo-1,4-naphthoquinone (213 mg, 0.845 mmol) and benzoylchloride (2 mL) was refluxed for 5 h at high temperature. The reaction mixture was cooled to room temperature, filtered under suction, washed with diethyl ether and air dried to obtain a brown solid. The crude product was triturated in diethyl ether and then further purified by column chromatography on silica gel 
X-ray crystallography
Crystals of compound 10 was obtained from a mixture of ethanol/dichloromethane via slow evaporation of the solvent at room temperature. Analysis was done with the Oxford Diffraction Gemini-R diffractometer. The crystal data and structure refinement parameters are available [18] . The overall molecular geometry with the atomic number scheme is shown in Fig. 1(a) , while the molecular packing is shown in Fig. 1(b) . Figure 1 (a) showed that 10 is a distorted planar structure. This distortion is due to the rotation about the C1-C12 single bond. The packing pattern, in Fig. 1(b) illustrates the molecules inversely stacked.
Results and discussion
Naphthoquinones with fused five-membered rings have been shown to reduce multidrug resistance and potentially increase cytotoxicity [19] . In order to obtain a series of 2-arylnaphtho[2,3-d]oxazole-4,9-dione (oxazolo-1,4-naphthoquinone) derivatives for bioactivity studies, a one-pot synthesis of 2-aryl substituted-oxazolo-1,4-naphthoquinone was accomplished as outlined in Scheme 1. The reaction of benzoyl chloride derivatives with 2-amino-3-bromo-1,4-naphthoquinone at elevated temperatures furnished the oxazolo-1,4-naphthoquione derivatives as brown/yellow solids with an average yield of 38%. This reaction is believed to proceed via the initial formation of the 2-amido-3-bromo-1,4-naphthoquinone derivative 7 (Scheme 1). A subsequent in situ intramolecular cyclization of the amidoderivative at reflux temperature then yielded the final target product. Formation of the oxazole product (8) (9) (10) (11) (12) under these conditions is temperature dependent as only the imido-and/ or amido-substituted derivatives are obtained at temperatures below 200°C. Purification of the crude product was accomplished by trituration followed by column chromatography on silica gel with appropriate solvent. Structure determination was carried out by studying their infrared,
C-NMR, and high resolution electrospray ionization mass spectrometric characteristics. These analogs underwent in vitro cytotoxicity studies on PC3 and LNCaP prostate cancer cell lines. Structure-activities-relationship (SAR) studies revealed how substitution at the ortho-, metaand para-positions of the oxazole substituent affected potency. Cytotoxicity studies on the fluoro-analog 12 also allowed us to compare the effect of more electronegative fluorine to that of the para-chloro-analog 9.
MTT assay was used to determine the anti-carcinogenic activities of these compounds on both androgen-dependent LNCaP and androgen-independent PC3 prostate cancer cell lines. The bio-activity screening revealed significant dosedependent and time-dependent cytotoxicity of the oxazolonaphthoquinones (Tables 1 and 2 ). After 5 days of exposure, these compounds showed the most potency for the androgen-dependent LNCaP with the ortho-chlorosubstituted analog 11 displaying the strongest cytotoxicity (IC 50 =0.01 μM) followed by the meta-chloro-analog 10 (IC 50 =0.03 μM). For androgen-independent PC3 prostate cancer cell lines, the most potent compounds appear to be the meta-chloro-analog 10 (IC 50 =0.08 μM) and the parachloro-analog 9 (IC 50 =0.08 μM). It thus appears that the meta-chloro-analog consistently displayed highly potent cytotoxicity regardless of whether the cell line is androgendependent (LNCaP) or androgen-independent (PC3). The para-chloro-analog 9 appears to display the lowest potency for LNCaP with an IC 50 of 0.40 μM after 120 h of exposure. The apparent loss of potency for compound 9 on LNCaP between 72 h and 120 h ( Table 2) was not observed on PC3 cell line (Table 1) in which there was a consistent time dependent cytotoxicity for all the five drugs studied. Further comparison of compound 9 with the para-fluoroanalog 12 revealed better activity of 12 (IC 50 =0.06 μM) on the androgen-dependent LNCaP prostate cancer cell line. On the other hand, comparison of the cytotoxicities of these two para-substituted analogs on the androgen-independent PC3 revealed a better potency for the p-chloro-analog 9 (IC 50 =0.08 μM) than the p-fluoro-analog 12 (IC 50 = 0.20 μM) after 5 days of exposure. Hence, both position and electronegativity of the substituent on the aryloxazole group appears to be important in modulating the cytotoxicity of this class of compounds.
In summary, the aryl-substituted oxazolonaphthoquinones in this study displayed potent cytotoxicity on both androgen-dependent LNCaP and androgen-independent PC3 prostate cancer cell lines with IC 50 range of 0.01-0.40 μM and 0.08-0.36 μM, respectively after 5 days of drug exposure. The meta-chloro-analog 10 appears to display very potent cytotoxicity irrespective of the cell line. In addition, it appears there is generally a slightly stronger cytotoxicity on the androgen-dependent LNCaP than on the androgen-independent PC3 prostate cancer cell lines. We believe that these quinones exercise their cytotoxicity via a combination of mechanistic pathways and are currently investigating some of these in addition to developing other analogs for further SAR studies. An anticancer drug that exerts its effect via multiple mechanistic pathways might provide the answer for new generation of drugs that are able to overcome multidrug resistant cancer cells. These drugs may be able to inhibit cross communication among the different pathways that allow for cancer cell survival.
